Akeso Inc., a biotechnology company, has announced the approval to initiate a global, multicenter, randomized Phase II registrational trial for their PD-1/CTLA-4 bispecific antibody, cadonilimab. The trial, known as COMPASSION-36/AK104-225, has received regulatory clearance from both China's National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA). This trial will evaluate the efficacy of cadonilimab in combination with lenvatinib versus lenvatinib alone in treating advanced hepatocellular carcinoma $(HCC)$ in patients who have previously been treated with atezolizumab and bevacizumab. This approval marks a significant step for Akeso in addressing the global challenge of cancer immunotherapy resistance and advancing treatment options for patients with limited survival benefits from current therapies.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。